8-K: DarioHealth Amends Credit Terms, Resets Covenants

DarioHealth Corp. has amended its credit agreement with Callodine Commercial Finance, resetting financial covenants, adjusting liquidity requirements, and modifying warrant terms.

Summary

• DarioHealth Corp. entered into an amendment to its existing credit agreement with Callodine Commercial Finance, LLC on November 5, 2025.
• The amendment resets financial covenants and waives financial-covenant testing for the second and third quarters of 2025.
• The minimum cash covenant was replaced with a $10,000,000 minimum consolidated unencumbered liquid assets covenant.
• A monthly 13-week cash-flow reporting requirement is introduced when liquidity falls below $11,000,000, subject to an EBITDA exception.
• An additional funding of $2,500,000 (Tranche B Term Loan) by the Lenders is clarified as uncommitted and at the Lenders' discretion.
• The exit fee was increased by an additional $150,000, which may be waived if a change-of-control prepayment fee is triggered.
• The company paid an amendment fee of $150,000 to Callodine Commercial Finance, LLC.
• The exercise price of Lender Warrants was reduced from $16.556 (post reverse stock split) to $15.3495 per share.
• The conversion price of up to $2,500,000 of the Callodine Loan Facility was reduced from $19.866 (post reverse stock split) to $15.3495.
• The original Credit Agreement was dated April 30, 2025, with a Term Loan Commitment of $35,000,000, including a $32,500,000 Tranche A Term Loan.
• The Term Loan Maturity Date is April 30, 2030, with interest at Term SOFR Rate plus 7.75%.
• Quarterly principal payments of $1,367,000 (or $2,050,000 if Tranche B is funded) commence in May 2028.

Sentiment

Score: 3

Explanation: The amendment provides necessary financial flexibility by resetting covenants and waiving near-term testing, which is crucial for the company's operational continuity. However, the terms reflect underlying financial pressures, including an increased cost of debt (higher exit fee), the dilutive nature of the warrant repricing, and the uncommitted nature of future funding tranches. The 'Equity Cure' provision further highlights potential future capital needs, indicating a challenging financial outlook despite the immediate relief.

Positives

• Waiver of financial-covenant testing for the second and third quarters of 2025 provides immediate financial flexibility.
• Reset of financial covenants offers more achievable targets for the company's current operational state.
• The amendment allows for potential additional funding of $2,500,000 (Tranche B) and $15,000,000 (Tranche C), although these are uncommitted.

Negatives

• The exit fee was increased by an additional $150,000, increasing the overall cost of the debt facility.
• The reduction in the warrant exercise price from $16.556 to $15.3495 per share is dilutive for existing shareholders.
• The additional funding tranches (Tranche B and C) are uncommitted and at the Lenders' sole discretion, introducing uncertainty regarding future capital access.
• The company paid an amendment fee of $150,000 for these changes.

Risks

• Failure to meet the new minimum consolidated unencumbered liquid assets covenant of $10,000,000.
• Inability to secure the uncommitted Tranche B ($2,500,000) and Tranche C ($15,000,000) Term Loans, which are at the Lenders' discretion.
• Potential for further dilution if the company utilizes the 'Equity Cure' provision to address Adjusted EBITDA covenant breaches.
• Ongoing negative Adjusted EBITDA targets for the near future, indicating continued unprofitability.
• The requirement for monthly 13-week cash-flow reporting when liquidity is below $11,000,000 indicates tight cash management and potential liquidity concerns.

Future Outlook

The company is focused on managing its debt and liquidity, with future funding (Tranche B and C) being discretionary for lenders, indicating potential reliance on future performance or capital raises. The reset of covenants suggests a need for more flexibility in the near term to navigate financial challenges.

Industry Context

The amendment reflects a common practice in the healthcare technology sector where companies, particularly those in growth phases, often require flexible financing structures and may need to renegotiate terms as their financial performance evolves. The reliance on discretionary funding and equity cure provisions highlights the inherent risks and capital intensity often associated with developing and commercializing health tech solutions.

Comparison to Industry Standards

• The interest rate (Term SOFR Rate + 7.75%) and various fees (closing, exit, agent) are typical for venture debt or growth capital facilities provided to companies in the health technology space, which often carry higher risk profiles than more mature industries.
• The inclusion of an 'Equity Cure' provision is a standard feature in many growth-stage debt agreements, offering a mechanism for companies to rectify covenant breaches through capital injections rather than immediate default, similar to agreements seen with companies like Teladoc Health or Livongo (prior to acquisition) in their earlier stages.
• The uncommitted nature of Tranche B and C funding is a common characteristic of such facilities, where future tranches are contingent on achieving specific milestones (e.g., Tranche B Milestone of $42,500,000 Total Revenue and 75% Gross Margin) or at the lender's discretion, reflecting a cautious approach by lenders to manage risk in volatile sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from the reduced warrant exercise price and the 'Equity Cure' provision. The increased cost of debt could also impact future profitability and shareholder returns.
• Lenders (Callodine Commercial Finance, LLC): Gain enhanced security and oversight through board observation rights and stricter liquidity reporting. However, the uncommitted nature of future tranches indicates a cautious stance on further capital deployment.
• Management: Will operate under tighter financial covenants and increased reporting requirements, particularly regarding liquidity and cash flow, necessitating disciplined financial management.
• Employees, Customers, Suppliers: No direct impact is immediately apparent, but the company's ongoing financial stability, influenced by these debt terms, could indirectly affect operational continuity and relationships.

Next Steps

• Secure IIA Consent with respect to IIA Funded IP within 21 days from April 30, 2025.
• Deliver fully-executed Account Control Agreements for US Deposit Accounts within 30 days from April 30, 2025.
• Deliver fully-executed Collateral Access Agreements for inventory locations within 30 days from April 30, 2025.
• Institute a trade secret protection program within 30 days from April 30, 2025.
• Deliver original share certificates and undated stock powers for Subsidiaries within 30 days from April 30, 2025.
• Provide evidence of Israel Security Documents filing with the Israeli Companies Registrar within 21 days from April 30, 2025.
• Provide evidence of Israel Security Documents registration and removal of Departing Lender Liens within 14 days from filing.
• Cause Twill, Ltd. to be wound down and dissolved or join the Guaranty and Collateral Agreement as a Loan Party within 3 months of April 30, 2025.
• Deliver consent from Bank Leumi LeIsrael for filing of Liens in favor of Agent within 14 days from November 5, 2025.
• Deliver a fully executed subordination agreement with WhiteHawk Capital Partners LP within 14 days from November 5, 2025.
• Provide monthly 13-week cash-flow reporting when Consolidated Unencumbered Liquid Assets are below $11,000,000 (subject to EBITDA exception).

Key Dates

Recommendation

The amendment provides necessary financial flexibility by resetting covenants and waiving near-term testing, which is crucial for the company's operational continuity. However, the terms reflect underlying financial pressures, including an increased exit fee and a reduced warrant exercise price, which is dilutive. The uncommitted nature of future funding tranches introduces uncertainty regarding capital availability. While the immediate crisis may be averted, the long-term financial health and path to profitability remain challenging, warranting a cautious 'hold' stance until clearer signs of sustainable improvement emerge.

Keywords

DarioHealth, DRIO, Credit Agreement, Financial Covenants, Warrants, Debt Financing, Liquidity, SEC Filing, Corporate Governance, Term Loan